Investing.com - Akari Therapeutics (NASDAQ:AKTX) reported on Tuesday second quarter earnings that matched analysts' forecasts and revenue that was inline with expectations.
Akari Therapeutics announced earnings per share of $0.00 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $0.00 on revenue of $0.00.
Akari Therapeutics shares are down 6.49% from the beginning of the year, still down 58.91% from its 52 week high of $4.21 set on February 22. They are under-performing the Nasdaq which is up 12.72% from the start of the year.
Akari Therapeutics follows other major Healthcare sector earnings this month
Akari Therapeutics's report follows an earnings beat by Cooper on June 3, who reported EPS of $3.38 on revenue of $719.5M, compared to forecasts EPS of $3.09 on revenue of $690.59M.
Adagene had matched expectations on June 2 with first quarter EPS of $-0.61 on revenue of $11M, compared to forecast for EPS of $-0.61 on revenue of $11M.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar